Allspring Global Investments Holdings LLC Has $178.81 Million Stake in Natera, Inc. (NASDAQ:NTRA)

Allspring Global Investments Holdings LLC cut its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 9.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,113,748 shares of the medical research company’s stock after selling 115,810 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.84% of Natera worth $178,805,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in NTRA. Blue Trust Inc. boosted its holdings in shares of Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after acquiring an additional 97 shares during the period. Versant Capital Management Inc boosted its stake in Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the period. Covestor Ltd boosted its stake in Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares during the period. GAMMA Investing LLC grew its holdings in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares in the last quarter. Finally, True Wealth Design LLC bought a new position in Natera during the 3rd quarter worth $57,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on NTRA shares. Craig Hallum boosted their target price on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. TD Cowen boosted their price objective on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Guggenheim raised their target price on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Canaccord Genuity Group lifted their price target on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Finally, StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $165.88.

Natera Stock Performance

Shares of NTRA stock opened at $169.71 on Wednesday. Natera, Inc. has a twelve month low of $67.33 and a twelve month high of $183.00. The stock’s fifty day simple moving average is $167.72 and its 200 day simple moving average is $141.94. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same quarter in the prior year, the firm posted ($0.95) earnings per share. The firm’s revenue was up 63.9% compared to the same quarter last year. On average, sell-side analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Solomon Moshkevich sold 4,858 shares of Natera stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $166.59, for a total value of $809,294.22. Following the transaction, the insider now directly owns 114,912 shares of the company’s stock, valued at $19,143,190.08. The trade was a 4.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John Fesko sold 663 shares of the business’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares in the company, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 312,394 shares of company stock valued at $52,333,520 in the last ninety days. 7.60% of the stock is currently owned by insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.